Hematologic Oncology

A focus on her passion for leukemia research and genuine care for her patients enabled Wendy Stock, MD, to rise above—one step at a time—as a mentor, leader, and pioneer.

The top 5 OncLive TV videos of the week cover insights in ALL, breast cancer, lung cancer, and pancreatic cancer.

The FDA approved subcutaneous mosunetuzumab for relapsed/refractory follicular lymphoma and granted a pair of breakthrough therapy designations.

Yannis K. Valtis, MD, discusses real-world outcomes for obecabtagene autoleucel and brexucabtagene autoleucel in relapsed/refractory acute lymphoblastic leukemia.

Obe-cel was associated with lower rates of CRS and ICANS vs brexu-cel in relapsed or refractory acute lymphoblastic leukemia.

Neha Mehta-Shah, MD, discusses the reasons she pursued a career specializing in treating patients with lymphoma.

Tsewang Tashi, MD discusses updated long-term data for avapritinib in indolent systemic mastocytosis from part 3 of the PIONEER trial.

Bezuclastinib normalized key bone marrow pathology in nonadvanced systemic mastocytosis.

Tsewang Tashi, MD, discusses long-term avapritinib data in indolent systemic mastocytosis from part 3 of the PIONEER trial.

Andre Henri Goy, MD, discusses key developments in mantle cell lymphoma presented at the 2025 ASH Annual Meeting.

The FDA has granted accelerated approval to subcutaneous mosunetuzumab for relapsed/refractory follicular lymphoma after 2 prior therapies.

The top 5 OncLive TV videos of the week cover insights in myeloma, AML, Ph-positive ALL, pediatric low-grade glioma, and nonadvanced systemic mastocytosis.

Experts reflect on pivotal data, emerging agents, and highly-anticipated trends spanning CML, CLL, B-cell lymphomas, and other hematologic malignancies.

Frontline dasatinib was linked to frequent T315I mutations at relapse in Ph+ ALL, while ponatinib showed fewer resistance mutations and favorable outcomes.

Tafasitamab plus lenalidomide and rituximab has been approved by the European Commission in relapsed/refractory follicular lymphoma.

Eytan M. Stein, MD, discusses the significance of the FDA approval of revumenib as a targeted therapy for relapsed/refractory, NPM1-mutant AML.

Anand Patel, MD, shares primary efficacy results from a phase 2 study evaluating a TKI plus inotuzumab ozogamicin–based therapy in newly diagnosed Ph-positive ALL.

Revumenib displayed responses irrespective of disease subtype in relapsed/refractory acute leukemia harboring a KMT2A rearrangement.

The top 5 OncLive TV videos of the week cover insights in acute myeloid leukemia, follicular lymphoma, multiple myeloma, and Ph+ B-ALL.

With longer median follow-up, talquetamab plus pomalidomide produced an ORR of 85.7% in patients with relapsed/refractory multiple myeloma in MonumenTAL-2.

The FDA approved Akeega for use in BRCA2+ mCSPC, granted priority review to the sBLA for nivolumab plus AVD in classical Hodgkin lymphoma, and more.

TERN-701 yielded a high response rate with deep molecular responses in patients with heavily pretreated chronic phase chronic myeloid leukemia.

Experts reflect on pivotal data from the 2025 ASH Annual Meeting that are set to change practice in AML, MZL, FL, and multiple myeloma.

The FDA has accepted and granted priority review to the sBLA for nivolumab plus AVD in untreated adult and pediatric classical Hodgkin lymphoma.

Sankalp Arora, MD, discusses the efficacy of azacitidine/venetoclax/gilteritinib in newly diagnosed, adverse-risk, FLT3 wild-type acute myeloid leukemia.